Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

This study has been completed.
Sponsor:
Information provided by:
Santen Oy
ClinicalTrials.gov Identifier:
NCT00596791
First received: January 8, 2008
Last updated: January 9, 2009
Last verified: January 2009

January 8, 2008
January 9, 2009
January 2008
July 2008   (final data collection date for primary outcome measure)
Change from screening in ocular symptoms and signs [ Time Frame: at week 6 and 12 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00596791 on ClinicalTrials.gov Archive Site
Safety and Quality of life parameters. [ Time Frame: From Screening (visit 1) to visits at week 2, 6 and 12. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

Not Provided
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Ocular Hypertension
  • Open-Angle Glaucoma
Drug: tafluprost
prostaglandine analoque
1 arm
Open-lable study with one arm.
Intervention: Drug: tafluprost
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
August 2008
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Finland
 
NCT00596791
Santen-77552, EudraCT number 2007-004872-37
No
Auli Ropo, Study Director, Santen Oy
Santen Oy
Not Provided
Principal Investigator: Hannu Uusitalo, Professor Finn-Medi Research, Finland
Santen Oy
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP